<DOC>
	<DOCNO>NCT02736565</DOCNO>
	<brief_summary>Ewing 's sarcoma characterize ( 11 ; 22 ) ( q24 ; q12 ) translocation several prioritize breakpoint site , result EWS/FLI1 fusion gene second frequently diagnose primary malignant bone tumor US annual incidence , birth age 20 , 2.9 case per million population . The survival rate patient high-risk recurrent disease ( relapse &lt; 2 year ) &lt; 10 % 5 year . Moreover , patient progress second line treatment , eighty percent achieve second complete response patient &lt; 10 % survive one year . Refractory patient frontline second line therapy even bad prognosis . The EWS/FLI1 gene well know driver gene Ewing 's sarcoma . We design novel pbi-shRNA™ EWS/FLI1 Type 1 LPX demonstrate sufficient specificity , safety efficacy animal test justify Phase I test . Clinical safety ( ≥ grade 3 product relate toxic effect ) target specific activity observe bi-shRNA product involve 147 cancer patient ( 698 separate dose administration ) ( BB-IND 14205 ; BB-IND 14938 ) . Moreover , safety observe IV delivery pbi-shRNA™ EWS/FLI1 Type 1 LPX murine swine test via multidose IV administration . Study test pbi-shRNA™ EWS/FLI1 Type 1 LPX involve patient ( ≥age 8 ) advance Ewing 's sarcoma . The first 3 subject enrol onto study well first subject enrol dose cohort must 16 year age old . pbi-shRNA™ EWS/FLI1 Type 1 LPX give via intravenous infusion twice week 4 week ( e.g . Mon Thurs , prefer ) total 8 infusion product per cycle follow 2 week washout period . Patients accrue 3-patient dose escalation cohort use follow escalation schema ( 50 % 33 % 25 % 25 % 25 % ) start IV dose 0.04 mg/kg .</brief_summary>
	<brief_title>Pbi-shRNA™ EWS/FLI1 Type 1 LPX Subjects With Advanced Ewing 's Sarcoma</brief_title>
	<detailed_description />
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Ewing</mesh_term>
	<criteria>Subjects eligible registration meet follow inclusion criterion : 1 . Histologically confirm Ewing 's Sarcoma Family Tumors ( ESFT ) . 2 . Age ≥8 year . 3 . Evidence EWS translocation fusion FISH RTPCR NGS . 4 . Evidence Type 1 fusion molecular diagnostics . 5 . Refractory intolerant standard care . 6 . ECOG performance status ( PS ) = 02 , Karnofsky PS ≥60 % Lansky PS ≥60 % . 7 . Normal organ marrow function define : Absolute granulocyte count ≥1,000/mm3 Absolute lymphocyte count ≥400/mm3 Platelets ≥100,000/mm3 Total bilirubin ≤ institutional upper limit normal AST ( SGOT ) /ALT ( SGPT ) ≤2x institutional upper limit normal Creatinine &lt; 1.5 mg/dL 8 . Subject recover CTCAE Grade 1 good adverse event associate prior therapy surgery . Preexisting motor sensory neurologic pathology symptom must recover CTCAE Grade 2 better . 9 . If female childbearing potential , negative urine serum pregnancy test . If urine test positive confirm negative , negative serum test require study entry . 10 . Ability understand willingness sign write inform protocol specific consent . Pediatric patient must sign assent parent legal guardian sign write informed consent , per institutional guideline . Subjects NOT eligible study registration enrollment meeting follow criterion : 1 . Anticancer chemotherapy , biologic therapy immunotherapy within 3 week radiation therapy within 2 week first infusion . 2 . Known history malignancy unless undergone curative intent therapy without evidence disease ≥ 3 year except cutaneous squamous cell basal cell skin cancer , superficial bladder cancer , situ cervical cancer situ cancer allow definitively resect . 3 . Brain metastasis unless treat curative intent ( gamma knife surgical resection ) without evidence progression ≥ 2 month . 4 . History current evidence condition ( include medical , psychiatric substance abuse disorder ) , therapy , laboratory abnormality might confound result study , interfere subject 's participation full duration study , best interest subject participate , opinion Investigator . 5 . Known HIV chronic Hepatitis B C infection .</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>metastatic</keyword>
	<keyword>askin tumor</keyword>
	<keyword>neuroectodermal tumor</keyword>
	<keyword>pNET</keyword>
	<keyword>sarcoma</keyword>
	<keyword>soft tissue</keyword>
</DOC>